These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 31698564)

  • 21. CBX1 is involved in hepatocellular carcinoma progression and resistance to sorafenib and lenvatinib via IGF-1R/AKT/SNAIL signaling pathway.
    Zheng SS; Wu JF; Wu WX; Hu JW; Zhang D; Huang C; Zhang BH
    Hepatol Int; 2024 Oct; 18(5):1499-1515. PubMed ID: 38769286
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of cFLIP overcomes acquired resistance to sorafenib via reducing ER stress‑related autophagy in hepatocellular carcinoma.
    Liu D; Fan Y; Li J; Cheng B; Lin W; Li X; Du J; Ling C
    Oncol Rep; 2018 Oct; 40(4):2206-2214. PubMed ID: 30066934
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exosomal miR-93 derived from hepatocellular carcinoma cell promotes the sorafenib resistance of hepatocellular carcinoma through PTEN/PI3K/Akt pathway.
    Bao Y; Xu S; Zhou J; Zhao C; Dai S; Zhang Y; Rao M
    J Biochem Mol Toxicol; 2024 Mar; 38(3):e23666. PubMed ID: 38375688
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
    Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J
    PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Is a Novel Prognostic Marker and Contributes to Sorafenib Resistance in Hepatocellular Carcinoma.
    Dietrich P; Gaza A; Wormser L; Fritz V; Hellerbrand C; Bosserhoff AK
    Neoplasia; 2019 Mar; 21(3):257-268. PubMed ID: 30685691
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
    Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma.
    Lu S; Yao Y; Xu G; Zhou C; Zhang Y; Sun J; Jiang R; Shao Q; Chen Y
    Cell Death Dis; 2018 May; 9(6):646. PubMed ID: 29844385
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interaction of key pathways in sorafenib-treated hepatocellular carcinoma based on a PCR-array.
    Liu Y; Wang P; Li S; Yin L; Shen H; Liu R
    Int J Clin Exp Pathol; 2015; 8(3):3027-35. PubMed ID: 26045814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulation of SIRT3 expression through CDK4/6 enhances the anti-cancer effect of sorafenib in hepatocellular carcinoma cells.
    Jo H; Park Y; Kim T; Kim J; Lee JS; Kim SY; Chung JI; Ko HY; Pyun JC; Kim KS; Lee M; Yun M
    BMC Cancer; 2020 Apr; 20(1):332. PubMed ID: 32306906
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exosomal MiR-744 Inhibits Proliferation and Sorafenib Chemoresistance in Hepatocellular Carcinoma by Targeting PAX2.
    Wang G; Zhao W; Wang H; Qiu G; Jiang Z; Wei G; Li X
    Med Sci Monit; 2019 Sep; 25():7209-7217. PubMed ID: 31553714
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thyroid hormone T3 augments the cytotoxicity of sorafenib in Huh7 hepatocellular carcinoma cells by suppressing AKT expression.
    Uyulgan S; Köse SN; Kıpçak A; Başkan Y; Dağlar G; Karagonlar ZF; Yandım C
    J Cancer Res Ther; 2024 Apr; 20(3):755-762. PubMed ID: 39023579
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MiRNA-124-3p.1 sensitizes hepatocellular carcinoma cells to sorafenib by regulating FOXO3a by targeting AKT2 and SIRT1.
    Dong ZB; Wu HM; He YC; Huang ZT; Weng YH; Li H; Liang C; Yu WM; Chen W
    Cell Death Dis; 2022 Jan; 13(1):35. PubMed ID: 35013144
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PMPCB Silencing Sensitizes HCC Tumor Cells to Sorafenib Therapy.
    Zheng JF; He S; Zeng Z; Gu X; Cai L; Qi G
    Mol Ther; 2019 Oct; 27(10):1784-1795. PubMed ID: 31337603
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Sestrin 2(SESN2) promotes primary resistance to sorafenib by activating AKT in hepatocellular carcinoma cells].
    Dai J; Niu K; Wang B; Li Y; Xia C; Tao K; Dai J
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2018 May; 34(5):427-433. PubMed ID: 30043734
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BEX1 mediates sorafenib resistance in hepatocellular carcinoma by regulating AKT signaling.
    Zhuang N; Gu Z; Feng J; Chai Z; Shan J; Qian C
    Cell Signal; 2023 Aug; 108():110722. PubMed ID: 37209973
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of key pathways and biomarkers in sorafenib-resistant hepatocellular carcinoma using bioinformatics analysis.
    Huang D; Yuan W; Li H; Li S; Chen Z; Yang H
    Exp Ther Med; 2018 Sep; 16(3):1850-1858. PubMed ID: 30186410
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fibrinogen-Like Protein 1 Modulates Sorafenib Resistance in Human Hepatocellular Carcinoma Cells.
    Son Y; Shin NR; Kim SH; Park SC; Lee HJ
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069373
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of core genes and outcomes in hepatocellular carcinoma by bioinformatics analysis.
    Shen S; Kong J; Qiu Y; Yang X; Wang W; Yan L
    J Cell Biochem; 2019 Jun; 120(6):10069-10081. PubMed ID: 30525236
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The hsa_circRNA_102049 mediates the sorafenib sensitivity of hepatocellular carcinoma cells by regulating
    Wang S; Liu D; Wei H; Hua Y; Shi G; Qiao J
    Bioengineered; 2022 Feb; 13(2):2272-2284. PubMed ID: 35034536
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
    Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
    Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.